Anagliptin ( INN; trade name Suiny) is a pharmaceutical drug for the treatment of type 2 diabetes mellitus. It is approved for use in Japan. It belongs to the class of anti-diabetic drugs known as dipeptidyl peptidase-4 inhibitors or "gliptins".

Research

A systematic review and meta-analysis of anagliptin, published in 2024, found that it is effective in lowering blood glucose in people with type2 diabetes and that it may lower cholesterol.

References

Dipeptidyl peptidase-4 inhibitors Nitriles Pyrazolopyrimidines {{gastrointestinal-drug-stub